MedTrace Logo

Desidustat in the Treatment of Anemia in CKD on Dialysis Patients

NCT04215120 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 392

Last updated 2021-11-24

No results posted yet for this study

Summary

A phase 3, multicenter, open-label, randomized, active-controlled study to evaluate the efficacy and safety of Desidustat Tablet versus Epoetin alfa Injection for the treatment of anemia in patients with CKD on dialysis. (DREAM-D)

Conditions

  • Chronic Kidney Disease Stage 5 on Dialysis

Interventions

DRUG

Desidustat Oral Tablet

Desidustat tablet

DRUG

Epoetin Alfa

Epoetin Injection

Sponsors & Collaborators

Principal Investigators

  • Dr Deven Parmar, MD · Zydus Lifesciences Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-04
Primary Completion
2021-09-02
Completion
2021-09-02

Countries

  • India

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04215120 on ClinicalTrials.gov